Werewolf Therapeutics rises on early-stage data for lead drug

Werewolf Therapeutics

03/11/2023 12:23

** Shares of biopharma co Werewolf Therapeutics  HOWL.O 
rise 40% to $3.01 premarket
    ** Co announces prelim first-in-human clinical data from
initial monotherapy dose-escalation cohorts of its lead
candidate
    ** Co studying WTX-124 as a monotherapy and in combination
with Merck's  MRK.N  Keytruda in early-stage trial in patients
with types of solid tumor cancer
     ** Safety data indicates WTX-124 is generally
well-tolerated - HOWL
    ** Adds WTX-124 provides compelling early evidence of
dose-dependent biomarker and antitumor activity in patients
    ** Up to last close, stock up ~5% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))